MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	10/22/2004 1:29:22 AM
	Read Replies (2) of 1826

MGI Pharma initiated with "neutral weight" - update Thursday, October 21, 2004 4:39:17 AM ET Prudential Financial NEW YORK, October 21 (newratings.com) - Analyst Jason Zhang of Prudential Financial initiates coverage of MGI Pharma Inc (MOGN.NAS) with a "neutral weight" rating. The 12-18 month target price is set to $30. In a research note published yesterday, the analyst mentions that the company is poised to benefit in the forthcoming years from its key product, Aloxi, for the treatment of chemotherapy-induced nausea and vomiting (CINV). MGI Pharma's stock performance is likely to be driven in the near term by Dacogen's regulatory progress, the ongoing clinical trials for the recently acquired products and Aloxi's sales, the analyst says. Prudential Financial believes, however, that the company stock is fairly valued at present.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next